Hybrid sales force

Quote












anonymous said:
When I get a yeast infection I can
1) go right away to Walmart/CVS and buy Monistat for $10 and start treatment immediately. BTW, I have never even needed/chosen to go to my doctor to get treatment for a yeast infection, except maybe my first one when I was a teen.
2) call my doctor and try to get an appointment as soon as possible ("soon", haha- and don't forget the cost of the appt). The Dr will offer me diflucan for $7 or I can consider this new expensive product that will require a prior auth or copay card hassle.

Consider in a well published journal article "Single-dose oral fluconazole versus single-dose topical miconazole for the treatmetn of acute vulvovaginal candidosis" by AM Van Heusden:

Clinical cure or improvement (investigators' assessment) was obtained in 100% (short-term) and 95% (long term) of the fluconazole group and in 94% and 90%, respectively, of the miconazole group. Mycological cure was achieved in 98% (short-term) and 73% (long-term) of the fluconazole group and in 96% and 82% respectively in the miconazole group.

Most patients do well with traditional treatments. For a product that most likely will be third line, how many patients does that leave with a need to be treated? Some, but NOT many= HARD sell.
Click to expand...
For someone who has no interest in using this product, you sure give a great deal of your time obsessing about it. Why not just let us go and launch our drug and you go off and do whatever it is that makes you happy? You don’t sound healthy right now.
 






This contract is total garbage. Fake two-faced recruiters..Amplity wants to pay peanuts to talented ppl and then will let the reps get abused by Scynexis. Drug is good but it takes more than just efficacy for a drug to gain adoption.
 






























The sales expectations for August is high and won’t get the amount scripts we need to make bonus. There’s a buy done program right now cause no contracts and eventually will need a prior auth which offices won’t do for this product.
 












anonymous said:
No, it’s not. The bad publicity hurt our launch, docs aren’t into it-too expensive, no coverage, not necessary.

Goals are unattainable, no, it’s not going well.. the real question is what will leadership do next
Click to expand...

I couldn’t disagree more.

im getting tons of buy in from the doctors I am able to see, my only problem so far is limited access due to the pandemic.

This drug has serious potential, if you can’t sell the value of 28 dollars more than flucanazole, then time to leave pharma.

I wish leadership would be more patient before doing field rides, but this is a really fun product to sell.

if you can’t enjoy a launch experience, you are in the wrong industry.
 






anonymous said:
I couldn’t disagree more.

im getting tons of buy in from the doctors I am able to see, my only problem so far is limited access due to the pandemic.

This drug has serious potential, if you can’t sell the value of 28 dollars more than flucanazole, then time to leave pharma.

I wish leadership would be more patient before doing field rides, but this is a really fun product to sell.

if you can’t enjoy a launch experience, you are in the wrong industry.
Click to expand...

NICE TRY DM D-BAG...
No one is buying your b.s.
 












This whole talk of hybrid...I get the face-to-face stuff. But does bringing in virtual help? Do doctors want to talk to you via virtual tech? Or is it just a short-term pandemic patch?
 




































anonymous said:
Two were let go. One left on their own. Read the tea leaves
Click to expand...

They were all let go.

The resignation was allowed to save face.

This is the most turnover I have observed at launch. Something is not right on this project.

Three higher ups at Scynexis, now a bunch of managers at Amplity, a few reps left early, and an MSL.

There has been poor management on both sides.

Too bad, it’s a good drug.
 






Top Bottom
Back
Quote